drugset / Trial / NCT06816433

Summary

This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for Post Traumatic Stress Disorder (PTSD) utilizing an adaptive platform trial (APT) design. Intervention D - SLS-002 will assess the safety and efficacy of SLS-002 in participants with PTSD. Please see NCT05422612 for information on the S-21-02 Master Protocol.

Timeline

Start
2028-05
Primary completion
2029-05
Completion
2029-07

Drugs

EvaluationDrugModalityDoseRoute
Subject SLS-002 Unknown 78 mg Intranasal